Vascular Solutions Beats on EPS But GAAP Results Lag
Vascular Solutions (NAS: VASC) reported earnings on Oct. 18. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended Sep. 30 (Q3), Vascular Solutions met expectations on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue grew slightly and GAAP earnings per share contracted significantly.
Margins shrank across the board.
Vascular Solutions tallied revenue of $24.6 million. The five analysts polled by S&P Capital IQ foresaw a top line of $24.8 million on the same basis. GAAP reported sales were 1.0% higher than the prior-year quarter's $24.3 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.16. The four earnings estimates compiled by S&P Capital IQ forecast $0.15 per share. GAAP EPS of $0.16 for Q3 were 27% lower than the prior-year quarter's $0.22 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 66.7%, 260 basis points worse than the prior-year quarter. Operating margin was 16.9%, 540 basis points worse than the prior-year quarter. Net margin was 10.4%, 490 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $25.7 million. On the bottom line, the average EPS estimate is $0.17.
Next year's average estimate for revenue is $99.0 million. The average EPS estimate is $0.58.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 91 members out of 103 rating the stock outperform, and 12 members rating it underperform. Among 24 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 19 give Vascular Solutions a green thumbs-up, and five give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Vascular Solutions is buy, with an average price target of $16.15.
- Add Vascular Solutions to My Watchlist.
The article Vascular Solutions Beats on EPS But GAAP Results Lag originally appeared on Fool.com.Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.